Search PubMed⌕ Search

Biomedical subjects

M Schata

Publications and source records attributed to M Schata.

10 recordsLinked to original sources
PubMed1997

[Quality assurance in allergology--the patient at the center].

The content and amount of the allergologic diagnostic measures differs more and more in comparison to the causal treatment and consulting of the patient during care. The tasks of quality assurance may include the development of criteria for evaluated diagnostic measures and the resulting treatment concepts with respect to an interdisciplinary approach. The cooperation with patient groups should be integrated in such a concept. The basic allergologic care, the interaction with allergologic centers, the supervision and coordination with facilities of in-patient care have to be newly defined in the frame of a structural discussion.

Adaptation, Psychological↗
PubMed1995

[Allergic diseases in the indoor environment].

Allergic diseases have severely increased worldwide through the last 30 years. More than 50% of all allergic diseases are caused by allergens out of the indoor environment. The most important allergen-carriers are cats, mites and molds. Since the first energy-crisis in 1970 private houses and offices had to be saved from energy losts, which decreased the rate of air changing and increased the relative humidity in the indoor environment. The hygienic situation of air conditioning systems is often insufficient controlled and leads to microbiological contamination. In Germany the number of cats, kept in private homes has increased significantly. These are important facts which led to an increase of indoor air allergies. The greatest number of mites and mold allergens are to be found in mattresses and textile furnitures. For most of the allergens in indoor air the correlation between the sensitizing allergen concentration and onset of illness is unknown. Diagnostic and therapy of allergies in the indoor environment must be supported by prevention and eliminating the main sources of allergen exposure.

Air Conditioning↗
PubMed1994

Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis.

The efficacy and tolerability of intranasal azelastine (0.14 mg/nostril twice daily) and oral terfenadine (60 mg twice daily) were compared under double-blind conditions in two 6-week, multicenter, parallel-group studies, including 167 patients suffering from seasonal and 52 patients suffering from perennial allergic rhinitis. In both studies, patients were symptomatic on entry and showed significant improvement on both treatments within the first 8 d of therapy, showing little further improvement with continued treatment. Symptoms most pronounced on entry--nasal itching, rhinorrhea, sneezing, and nasal obstruction--responded best to treatment (response rates 80-90%). Objective signs such as mucosal swelling and conjunctivitis improved in a manner parallel to symptoms. In perennial rhinitis, azelastine showed a trend to a superior relief of rhinorrhea and nasal obstruction, whereas terfenadine showed a trend toward better control of sneezing and nasal itchiness. No clinically relevant or statistically significant differences between treatments could be identified. The incidence of adverse effects of possible causal relationship to therapy was low. The most frequent effects in azelastine-treated patients were related to application site disorders, e.g., nasal irritation. Results indicate that with the dose used azelastine nasal spray is an effective treatment for both seasonal and perennial allergic rhinitis.

Administration, Intranasal↗
PubMed1991

Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis.

The efficacy and safety of the nasal administration (twice in each nostril, four times a day) of levocabastine (0.5 mg/ml) were compared with those of sodium cromoglycate (20 mg/ml) and placebo in a 2-week, parallel, double-blind trial in patients with seasonal allergic rhinitis. At the end of treatment, 89% of patients in the levocabastine-treated group rated their treatment as globally good or excellent as compared with 32% (p = 0.003) of sodium cromoglycate-treated and 35% (p = 0.002) of placebo-treated patients. According to the investigators' ratings, the severest nasal symptom and ocular complaints responded better to levocabastine than to cromoglycate (p = 0.05 and p = 0.03) or placebo treatment (p = 0.03 and p = 0.001). Visual analogue scale ratings in patients' diaries indicated that at the end of therapy, nasal symptoms were less severe in the levocabastine-treated group than in the sodium cromoglycate-treated (p = 0.03) or placebo-treated group (p = 0.001). Total symptom severity as a percentage of the theoretical maximum symptom severity during the treatment period was lower for levocabastine than for sodium cromoglycate (p = 0.06) or placebo (p = 0.004) for the severest nasal symptom (35% versus 47% and 76%), sneezing (the most frequent symptom) (27% versus 42% and 67%), and itchy nose (18% versus 37% and 67%). The percentage of days at which nasal symptoms were entirely absent was markedly higher in the levocabastine-treated (33%) than in the sodium cromoglycate-treated (9%; p = 0.006) or placebo-treated (3%; p = 0.001) group.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Intranasal↗
PubMed1990

[Cefixime therapy in sinusitis].

In a clinical study, 40 patients suffering from acute, recurrent or chronic sinusitis were treated with cefixime. The duration of therapy ranged from seven to 15 days. The dosage was 200 mg bid. In all patients cure or a marked improvement of clinical symptoms was noticed. Ten patients suffered gastrointestinal side effects which were classified as mild to moderate; however, all the patients received a full treatment course.

Acute Disease↗
PubMed1978

Inhibitory effect of beta-adrenergic stimulants on the histamine reaction of the human skin. II. Studies with several derivatives in regard to the dosage used and reaction depending on time.

In 56 volunteers the inhibitory effects of the beta-adrenergic stimulants fenoterol, salbutamol, isoproterenol, orciprenaline, terbutaline, epinephrine and phenylephrine were studied. There was a difference between the substances in regard to the applied dose and duration of inhibitory effect. The latter parameter particularly depended on the hydrosolubility of the individual substances. Fenoterol and salbutamol had a very low solubility and a very strong and long-lasting effect. The possibly stronger adhesive power of these drugs in the tissue according to their poor solubility and the site of action in the reactive systems of the skin are discussed giving preference to the vascular system over the mast-cells and cAMP.

Adrenergic beta-Agonists↗
PubMed1976

Inhibitory effect of beta-adrenergic stimulants on the histamine reaction in human skin. I. Studies with fenoterol.

In 20 volunteers histamine inhibition by fenoterol (Th 1165 a) was studied. The wheal and erythema reaction caused by intracutaneous application of 5 mug histamine can be inhibited by applying fenoterol in doses from 100--400 mug in form of a metered aerosol on the skin 5 min before the injection of histamine. In this study the dose-reaction effect yielded on ED50 of 140 mug fenoterol.

Adrenergic beta-Agonists↗